Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $547,732.65 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 17,295 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the transaction, the executive vice president directly owned 85,755 shares of the company’s stock, valued at $2,715,860.85. This trade represents a 16.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Richard Daniell also recently made the following trade(s):

• On Tuesday, December 9th, Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $30.46 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The stock’s 50 day simple moving average is $33.00 and its two-hundred day simple moving average is $26.53. The company has a market cap of $35.02 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 10.55 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the prior year, the company earned $0.71 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TEVA. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Barclays raised their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $25,000. Allworth Financial LP increased its stake in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the period. Grove Bank & Trust raised its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the period. Finally, Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter valued at about $41,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.